GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 4d pharma PLC (OTCPK:LBPWQ) » Definitions » Net-Net Working Capital

LBPWQ (4d pharma) Net-Net Working Capital : $0.00 (As of Dec. 2021)


View and export this data going back to 2021. Start your Free Trial

What is 4d pharma Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

4d pharma's Net-Net Working Capital for the quarter that ended in Dec. 2021 was $0.00.

The industry rank for 4d pharma's Net-Net Working Capital or its related term are showing as below:

LBPWQ's Price-to-Net-Net-Working-Capital is not ranked *
in the Biotechnology industry.
Industry Median: 4.395
* Ranked among companies with meaningful Price-to-Net-Net-Working-Capital only.

4d pharma Net-Net Working Capital Historical Data

The historical data trend for 4d pharma's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

4d pharma Net-Net Working Capital Chart

4d pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Net-Net Working Capital
Get a 7-Day Free Trial - - - - -

4d pharma Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21
Net-Net Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of 4d pharma's Net-Net Working Capital

For the Biotechnology subindustry, 4d pharma's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


4d pharma's Price-to-Net-Net-Working-Capital Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 4d pharma's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where 4d pharma's Price-to-Net-Net-Working-Capital falls into.



4d pharma Net-Net Working Capital Calculation

4d pharma's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Dec. 2021 is calculated as

Net-Net Working Capital(A: Dec. 2021 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(20.608+0.75 * 2.882+0.5 * 0.362-26.253
-0-0)/0
=N/A

4d pharma's Net-Net Working Capital (NNWC) per share for the quarter that ended in Dec. 2021 is calculated as

Net-Net Working Capital(Q: Dec. 2021 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(20.608+0.75 * 2.882+0.5 * 0.362-26.253
-0-0)/0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.


4d pharma  (OTCPK:LBPWQ) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.


4d pharma Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of 4d pharma's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


4d pharma Business Description

Traded in Other Exchanges
N/A
Address
9 Bond Court, Fifth Floor, Leeds, GBR, LS1 2JZ
4d pharma PLC and its subsidiaries are in the business of research and development and production of live biotherapeutic products. The company develops biotherapeutic products for diseases such as cancer, asthma, autism, and autoimmune conditions such as arthritis and multiple sclerosis. Its developing science includes Live biotherapeutics, Microbiome, MicroRx, MicroDx, and others.